Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with advanced non-small-cell lung cancer (aNSCLC), but immune-related adverse events (irAEs) have been evidenced curtailed the clinical use of them. PURPOSE: The aim of this study was to research th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenhui, Liu, Yiping, Ma, Fang, Sun, Bao, Wang, Ying, Luo, Jianquan, Liu, Mouze, Luo, Zhiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850423/
https://www.ncbi.nlm.nih.gov/pubmed/33536784
http://dx.doi.org/10.2147/CMAR.S293200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850423/
https://www.ncbi.nlm.nih.gov/pubmed/33536784
http://dx.doi.org/10.2147/CMAR.S293200

Ejemplares similares